A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated ...

The Trump administration's cuts to HIV prevention will lead to new infections, medical costs and death, experts warn.

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Gilead's HIV franchise remains dominant, generating $19.612 billion in 2024, but faces potential funding challenges impacting future growth. Efforts to build a cancer franchise have been mixed ...

Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

Human immunodeficiency virus, if untreated, causes acquired immunodeficiency syndrome (AIDS), and death. HIV is almost entirely preventable by using condoms, or by taking PrEP drugs. PrEP drugs do not ...